ClinicalTrials.gg
CompletedNCT04742959Updated Apr 26, 2024

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of TT-00420 and Nab-Paclitaxel in Advanced Solid Tumor, Cholangiocarcinoma and HER2-negative Breast Cancer, sponsored by TransThera Sciences (Nanjing), Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-26.

Sponsored by TransThera Sciences (Nanjing), Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
203
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Enrollment
37th of 279
203 · median 44
Started
2021
with 24 others
Phase 1/2
42 of 328
12 open now
Registered
207th of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 37th largest by enrollment of the 279 interventional ones that give a count, is one of 25 that started in 2021, is one of 42 in phase 1/2, and was the 207th registered.

Cholangiocarcinoma

824 studies on the registry are indexed under Cholangiocarcinoma; 287 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.

Read the detailed description

Study consists of three arms, Arm A is a Phase Ib/II study of TT-00420 tablet monotherapy, Arm B is a Phase Ib/II study of TT-00420 tablet in combination with nab-paclitaxel (Abraxane®) and Arm C is a PK run-in study of TT-00420 tablet.

Arm A: TT-00420 Tablet Monotherapy Phase Ib will enroll patients with preferred indications including metastatic cholangiocarcinoma, HER2-negative breast cancer including TNBC, bladder cancer, small cell lung cancer, prostate cancer, thyroid cancer, sarcoma, gastric cancer, gallbladder cancer and other advanced solid tumors to receive TT-00420 monotherapy. Based on preliminary efficacy results, Phase II will enroll additional patients in select indications to evaluate the efficacy of TT-00420 monotherapy.

Arm B: TT-00420 tablet in combination with nab-paclitaxel (Abraxane®) Arm B will enroll patients with metastatic HER2-negative breast cancers, including triple-negative breast cancer (TNBC). Phase Ib will be a dose escalation study of TT-00420 in combination with nab-paclitaxel, guided by 3+3 design, to determine a Recommended Phase 2 Dose (RP2D). Phase II will enroll additional patients with metastatic HER2-negative breast cancers to further evaluate the efficacy of the combination regimen.

Arm C: PK Run-in Study of TT-00420 Tablet Arm C will enroll patients with preferred indications including cholangiocarcinoma, TNBC/HER2- negative breast cancer, prostate cancer, sarcoma, hepatocellular carcinoma (HCC), bladder cancer, small cell lung cancer, thyroid cancer, gastric cancer, gallbladder cancer and other advanced solid tumors to receive TT-00420 monotherapy administered as once daily (q.d.) or twice daily (b.i.d.).

03

Conditions studied

  • Advanced Solid Tumor
  • Cholangiocarcinoma
  • HER2-negative Breast Cancer
  • Triple Negative Breast Cancer
  • Bladder Cancer
  • Small-cell Lung Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Sarcoma
  • Gastric Cancer
  • Gallbladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age
  2. Histopathological or documented locally advanced or solid tumors who have no available standard therapeutic treatment options
  3. At least one as defined by V1.1 criteria for solid tumors
  4. (ECOG) performance status of 0 or 1
  5. Adequate organ function confirmed at screening and within 10 days of initiating treatment, as evidenced by:

    • (ANC) ≥ 1.5 x 10\^9/L
    • (Hgb) ≥ 8 g/dl
    • (plt) ≥ 75 x 10\^9/L
    • /SGOT and ALT/SGPT ≤ 2.5 x (ULN) or ≤ 5.0 x ULN if liver metastases are present
    • Total ≤ 1.5 x ULN
    • Calculated ≥ 50 mL/min (Cockcroft Gault formula)
  6. Negative pregnancy test within 72 hours before starting study treatment in all premenopausal women and women \< 12 months after the onset of menopause
  7. Must agree to take sufficient methods to avoid pregnancy during the study and until at least 6 months after ceasing study treatment
  8. Able to sign and comply with the protocol

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or lactating
  2. Women of (WOCBP) who do not use adequate
  3. Patients with any hematologic , including leukemia (any form), lymphoma, and multiple myeloma
  4. Patients with a history of primary central nervous system tumors or carcinomatous meningitis.
  5. Patients with the following mood disorders as judged by the Investigator or a psychiatrist:

    • Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia; a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)
    • ≥ grade 3 anxiety
  6. Impaired cardiac function or significant diseases, including but not limited to any of the following:

    • (LVEF) \< 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)
    • Congenital long syndrome
    • QTcF ≥ 480 msec on screening
    • Unstable angina pectoris ≤ 3 months prior to starting study drug
    • Acute myocardial infarction ≤ 3 months prior to starting study drug
  7. Patients with:

    • unresolved diarrhea ≥ CTCAE grade 2, or
    • impairment of gastrointestinal (GI) function, or
    • GI disease that may significantly alter the absorption of TT-00420
  8. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., uncontrolled hypertension, uncontrolled hypertriglyceridemia, or active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol
  9. Patients who have received chemotherapy, targeted therapy, or immunotherapy ≤ 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy
  10. Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  11. Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  12. Patients who have been treated with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF) ≤ 4 weeks prior to starting study drug.
  13. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium or any other coumarin-derivative anticoagulants
  14. Patients who have received systemic ≤ 2 weeks prior to starting study drug or who have not recovered from the side effects of such treatment.
  15. Patients who are currently receiving treatment with strong inhibitors or inducers ≤ 2 weeks prior to starting study drug.
  16. Known diagnosis of (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled)
  17. Known history of active infection with or
  18. Has received a live-virus vaccination within 30 days of planned first dose
  19. Inability to swallow or tolerate oral medication
  20. Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's safe participation and compliance in the trial.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Monotherapy Cohorts

    TT-00420 tablets will be administered once daily in 28-day cycles.

    Drug: TT-00420

  • Experimental
    Dose Escalation Cohorts (Combination Therapy)

    TT-00420 tablets will be administered once daily in 28-day cycles. Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Day 1, 8, and 15 of each 28-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).

    Drug: TT-00420 · Combination Product: Nab-Paclitaxel

  • Experimental
    PK Run-in Cohorts

    TT-00420 tablets will be administered once or twice daily in 28-day cycles according to assigned cohort.

    Drug: TT-00420

Interventions

  • TT-00420 tablet will be administered orally once daily per protocol defined schedule.

  • Combination productNab-Paclitaxel

    Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle

06

What researchers measure

Primary outcomes

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

    As assessed per NCI Common Toxicity Criteria for Adverse Events, version 5.0

    Time frame: Up to 30 days from study discontinuation

  2. Dose limiting toxicity (DLT)

    Dose escalation cohorts are monitored and assessed using the NCI Common Toxicity Criteria for Adverse Events, version 5.0.

    Time frame: Up to 28 days from the first dose

Secondary outcomes

  1. Objective Response Rate (ORR)

    The proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months.

  2. Disease Control Rate (DCR)

    Defined as CR + PR + stable disease (SD) based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months.

  3. Duration of Objective Response (DOR)

    Duration of response for CR or PR based on RECIST version 1.1.

    Time frame: Through study completion, an average of 9 months.

  4. Progression Free Survival (PFS)

    Time frame: From first study drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  5. Overall Survival (OS)

    Time frame: From first study drug administration until the date of death from any cause, assessed up to 24 months

  6. Area under the curve (AUC0-∞)

    Blood samples will be collected at designated time points for pharmacokinetic analysis of TT-00420 and/or nab-paclitaxel.

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 28 days)

  7. Area under the curve (AUC0-t)

    Blood samples will be collected at designated time points for pharmacokinetic analysis of TT-00420 and/or nab-paclitaxel.

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 28 days)

  8. Maximum observed concentration (Cmax)

    Blood samples will be collected at designated time points for pharmacokinetic analysis of TT-00420 and/or nab-paclitaxel.

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 28 days)

  9. Half-life (T1/2)

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 28 days)

  10. Time to Maximum Concentration (Tmax)

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 28 days)

  11. Volume of Distribution (Vd)

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 28 days)

Other outcomes

  1. Genetic Alteration Status

    Evaluation of biomarkers, including but not limited to, fibroblast growth factor receptor (FGFR) mutation status

    Time frame: Through study completion, an average of 9 months

07

Study locations

6 sites
  • City of Hope
    Duarte, California 91010, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • Rutgers Cancer Institute
    New Brunswick, New Jersey 08901, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Feb 2024, 35 months.

Of 40 phase 1/2 interventional studies under Cholangiocarcinoma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 77. This study's 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Feb 8, 2021
StartActual
Mar 14, 2021
Primary completionActual
Feb 20, 2024
CompletionActual
Feb 20, 2024
Last update
Apr 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04742959
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Responsible party
Sponsor
First posted
Feb 8, 2021
Start date
Mar 14, 2021
Primary completion
Feb 20, 2024
Completion
Feb 20, 2024
Last update
Apr 26, 2024

Study contacts

Sarina A. Piha-Paul, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinengotinib

Start the discussion